Conditions: Patients at Risk for Melanoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 100
Healthy volunteers: yes

Brief summary:
This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi from ultraviolet light (UV)-induced oxidative changes. The investigators will 1) evaluate whether administration of NAC around the time of UV exposure will reduce melanoma risk in high-risk patient populations with genetic susceptibility to UV-induced oxidative stress, and 2) examine key genetic variants that will identify which individuals are most likely to benefit from chemoprotection.

Detailed description:

Arms:
arm 1: Patients receiving NAC (N-acetylcysteine) arm 2: Participants not receiving NAC (N-acetylcysteine)

Interventions: intervention 1: N-acetylcysteine intervention 2: Placebo arm
Intervention descriptions: intervention 1: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses intervention 2: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.

Protocol document: